| Document |
Document Title |
|
WO/2024/071970A1 |
The present invention relates to: a fusion polypeptide comprising a His tag, and a peptide tag of which the main amino acids are charged amino acids; a fusion protein in which the fusion polypeptide and a target protein are fused; and a ...
|
|
WO/2024/068827A1 |
The invention relates to a method for manufacturing a precipitated mixture, which contains liraglutide or a salt thereof (component (A)), comprising the steps of removing solid parts, mixing with an antisolvent, stirring precipitation su...
|
|
WO/2024/067153A1 |
Provided are a nucleic acid for producing rAAV in an insect cell, a VP1 capsid protein mutant, and use. The nucleic acid comprises nucleotide sequences encoding adeno-associated viruses VP1, VP2, and VP3 proteins. Compared with the capsi...
|
|
WO/2024/073606A1 |
Methods for improving engraftment of donor cells in a subject thereof are provided. Such methods can comprise providing donor cells that have been modified to express a first isoform of a target protein (e.g., interleukin-2 receptor subu...
|
|
WO/2024/067723A1 |
A respiratory syncytial virus subtype A (RSV-A) recombinant F protein, a polynucleotide, a nucleic acid construct, an expression vector, a host cell, a stabilized trimer formed by the recombinant F protein, an immunogenic composition com...
|
|
WO/2024/068617A1 |
The present invention concerns a modified cell comprising a transgene coding for interleukin-2 (IL-2). Said modified cell comprises a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive pr...
|
|
WO/2024/073697A1 |
The disclosure relates to Respiratory Syncytial Virus (RSV) vaccine compositions having truncated mucin domains in the G-protein. In certain embodiments, this disclosure relates to virus particles, virus-like particles, virosomes, nuclei...
|
|
WO/2024/072958A1 |
The present invention relates to engineering synthetic major histocompatibility complex (MHC) molecules for generating universal peptide/MHC complexes with engineered disulfide linkage(s) using structure-guided modeling and design and me...
|
|
WO/2024/072954A1 |
A method to oxidize pan-cancer epitopes of COL6A3 protein (peptide sequences 1. FLLDGSANV (SEQ ID NO: 1), 2. FLLDGSEGV (SEQ ID NO: 2) and 3. FLLDGSINF (SEQ ID NO: 3)) by cold atmospheric plasma treatment for developing solid tumor cancer...
|
|
WO/2024/071043A1 |
Provided is a novel production method of a hetero that enables the production of a heteromultimeric protein such as a bispecific antibody. The production method of the present disclosure, which is for producing a heteromultimeric prote...
|
|
WO/2024/062417A1 |
The present disclosure relates to enzymes, compositions and methods for performing conditional homologous recombination of a targeted DNA molecule or genome by using modified proteins comprising nucleic acid DNA binding proteins with pro...
|
|
WO/2024/064446A2 |
Disclosed herein are compositions comprising a recombinant polypeptide targeting phosphatidylserine on the surface of cancer cells and methods of using the compositions to treat a cancer in a subject.
|
|
WO/2024/064744A2 |
Engineered split dihydrofolate reductase-based methods and systems are provided for selecting cells that have stably acquired a heterologous polynucleotide.
|
|
WO/2024/064782A2 |
Provided herein are recombinant adeno-associated virus (AAV) capsid proteins, compositions (e.g., rAAV) comprising the capsid proteins, nucleic acids encoding the capsid proteins, and methods of making and using the capsid proteins.
|
|
WO/2024/062149A1 |
The present invention relates to compounds, especially to conjugates and derivatives of alternariol labelled at specific positions in the molecule, suitable for the production of antibodies with a high affinity for alternariol. Likewise,...
|
|
WO/2024/061753A1 |
The present invention relates to trimeric class I fusion proteins, in particular to class I fusion proteins, comprising at least one stabilizing mutation in the HR2 domain, and to fragments thereof.
|
|
WO/2024/064860A1 |
Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a humanized or human T cell receptor (TCR) comprising a variable domain encoded by (a) at least one human TCR variable region γ...
|
|
WO/2024/064653A1 |
Provided herein, inter alia, are variant lectin anti-viral polypeptides as well as compositions and methods for expressing and using the same for the treatment and prevention of viral disease in animals.
|
|
WO/2024/064612A1 |
The present application concerns selected engineered analogs of atrial natriuretic peptides, compositions that contain these peptides and uses thereof to treat, prevent, or alleviate the symptoms of cardiovascular, cardiorenal, or metabo...
|
|
WO/2024/064640A2 |
Disclosed herein are chimeric antigen receptors (CARs) comprising an antigen binding site that recognizes citrullinated polypeptides. Citru llinated polypeptides, such as citrullinated vimentin, are expressed in the skin lesions of subje...
|
|
WO/2024/062098A1 |
The present invention relates to the field of viral immunotherapy. In particular, the invention concerns a novel recombinant pseudocowpox virus (PCPV) comprising a nucleic acid molecule inserted in its genome and encoding an interleukine...
|
|
WO/2024/064863A2 |
Provided herein are gene therapy compositions and methods of treating loss of cardiomyocyte alignment due to reduced levels of functional plakophilin-2 protein in a subject having arrhythmogenic cardiomyopathy. Also provided herein are g...
|
|
WO/2024/063611A2 |
The present invention relates to a hydroxy fatty acid and a hydroxy fatty acid derivative derived from long-chain fatty acids and functioning as agonists for fatty acid receptors such as GPR40 and GPR120. The hydroxy fatty acid and the h...
|
|
WO/2024/064856A1 |
Provided herein are gene therapy compositions and methods of treating reduced levels of functional cardiac myosin binding protein C in a subject having hypertrophic cardiomyopathy.
|
|
WO/2024/061239A1 |
Provided are a fusion protein for preventing or treating coronavirus infection, a Spike protein nanoparticle, and a preparation thereof. The fusion protein comprises a mutation-containing coronavirus Spike protein extracellular domain wh...
|
|
WO/2024/064802A2 |
Described and featured are immunogenic compositions comprising non-naturally occurring pan-fungal kexin peptides and methods of using such compositions for the treatment or prevention of various diseases or severe diseases, and/or the sy...
|
|
WO/2024/064763A2 |
Variants of coagulation factor VIII (FVIII) and expression cassettes encoding the FVIII variants thereof are described. A variant FVIII includes a glycoepitope of the FVIII protein including an N2118Q mutation. The N2118Q mutation can be...
|
|
WO/2024/064931A1 |
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of Plasmodium protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the pre...
|
|
WO/2024/064913A1 |
The present disclosure provides gene therapy vectors, such as recombinant adeno-associated virus (rAAV) for expressing a human micro-dystrophin gene. The present disclosure also provides compositions and methods of using these rAAV to tr...
|
|
WO/2024/064756A1 |
Disclosed are bispecific modulators. Bispecific modulators can bind to a protein of interest and to an internalizing receptor on a cell surface. Once bound, the protein of interest can be internalized and/or degraded inside a cell.
|
|
WO/2024/064200A2 |
The present disclosure provides compositions comprising a designed ankyrin repeat protein (DARPin) for use in treating Shiga toxin (Stx)-producing Escherichia coli (STEC) and related diseases, including hemolytic uremic syndrome (HUS). T...
|
|
WO/2024/064922A2 |
Compositions and methods for treating insulin resistance, reducing blood glucose level, increasing insulin tolerance, and treating diabetes. The methods include administering the composition to a subject. The subject may express insulin ...
|
|
WO/2024/064838A1 |
Provided herein are lipid particles, including viral-based particles, comprising Paramyxovirus glycoproteins having reduced glycosylation, and in some aspects, comprise variant G/H proteins. Also provided are methods for producing and mo...
|
|
WO/2024/061930A1 |
The present invention relates to treatment and diagnostic of peripheral t-cell lymphoma (PTCL). In this study, the inventors showed that cutaneous T-cell lymphoma (CTCL) lines and KIR3DL2+ SC are ICOS+ and ICOSL+. Normal T lymphocytes ar...
|
|
WO/2024/062259A1 |
The present invention relates to retroviral vectors modified to improve transgene expression. In particular, the invention relates to retroviral vectors lacking an endogenous Rev response element (RRE) and comprising an intron, particula...
|
|
WO/2024/064716A2 |
Isolated T cell receptors (TCRs) that specifically recognize a peptide derived from an HPV E6 or E7 protein are described. The TCRs include an alpha chain variable region and a beta chain variable region having the complementarity determ...
|
|
WO/2024/060948A1 |
The present invention relates to a T cell receptor (TCR) specifically binding to a human papillomavirus E7, a nucleic acid encoding the TCR, an engineered cell comprising same, and a method for preparing the engineered cell. The present ...
|
|
WO/2024/063538A1 |
The present invention relates to a composition for base editing of plant cell organelle DNA and, in particular, to a composition and method for editing adenine to guanine and cytosine to thymine in plant cell organelle DNA.
|
|
WO/2024/064855A2 |
The present application relates to chimeric antigen receptors (CARs), engineered immune cells (e.g., NK cells, NKT cells, and T cells), and methods of use thereof. The CARs provided herein can enhance the killing activities of the engine...
|
|
WO/2024/061310A1 |
The present invention provides a dual GLP-1 and GIP receptor agonist pharmaceutical composition, comprising a dual GLP-1 and GIP receptor agonist, a stabilizer, and a buffer salt. The present invention also provides a use of the pharmace...
|
|
WO/2024/064713A1 |
The disclosure provides antibodies or antigen-binding domains thereof specific for CD228 and fusion proteins specific for both CD137 and CD228, which fusion proteins can be used to co-stimulate lymphocyte activation in a CD228-target-dep...
|
|
WO/2024/064733A2 |
Genetically engineered immune cells (e.g., T cells or NK cells) expressing anti-BCMA, anti-TACI, or anti-BCMA/anti-TACI chimeric antigen receptors and uses thereof in cancer therapy. In some embodiments, the genetically engineered immune...
|
|
WO/2024/064752A2 |
Bio-adhesive derived from Vibrio cholerae (Vc) are provided. In some forms, the bio-adhesive includes a sequence of 57 amino acids within a major biofilm adhesin Bap1, and sequence variations thereof, that can be used as bioactive glue t...
|
|
WO/2024/063404A1 |
The present invention relates to a method for cultivating a botulinum toxin-producing strain to increase botulinum toxin productivity and to a method for effectively producing botulinum toxin by culturing a strain using the method. Throu...
|
|
WO/2024/061188A1 |
The present invention provides a coronavirus multivalent vaccine and use thereof. The coronavirus multivalent vaccine comprises a coronavirus Spike protein extracellular domain containing a mutation, a truncated fragment thereof, or a fu...
|
|
WO/2024/064839A2 |
Some aspects of the present disclosure are directed towards the concentration or reduction of a solution, formulation, mixture, or compound comprising a protein conjugated to a polymer. In some embodiments, the method can involve applyin...
|
|
WO/2024/060167A1 |
The present invention provides a fusion protein, which comprises: a tissue plasminogen activator or a variant thereof; a disintegrin or a variant thereof; and a connector. The connector connects the tissue plasminogen activator or the va...
|
|
WO/2024/064753A1 |
Disclosed are receptor traps that regulate immune cells. The receptor traps can have an ectodomain from a tumor cell that can bind to a chimeric antigen receptor (CAR) on a CAR-T cell that reversibly inhibits activation of the CAR-T cell.
|
|
WO/2024/062101A1 |
The invention relates to a bi-specific agent, comprising an anchor region capable of binding a plasma cell, and a binding region associated with the anchor region, wherein the binding region comprises an epitope of an interferon, an inte...
|
|
WO/2024/061757A1 |
The present invention relates to stabilized human parainfluenza virus 1 (HPIV1) F protein, and to nucleic acid sequences encoding such proteins, as well as to uses of said proteins and nucleic acid sequences.
|
